Skip to contentA
AbCellera Biologics Inc.
A
ABCLAbCellera Biologics Inc. Released Aug 12, 2021, after the close
10-Q filed Aug 13, 2021, 44 days after period end · 0001564590-21-044327
Q2 2021 · 10-Q
Revenue$27.64M$27.64M+146.2% vs Q2 2020−86.4% vs Q1 2021 Net Income-$2.32M-$2.32M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR
N/M vs Q1 2021
EPS Diluted-$0.01-$0.01N/M vs Q2 2020N/M vs Q1 2021 Operating Income-$7,033,000N/M Operating Cash Flowderived$157,683,000+507.0% Free Cash Flowderived$120,879,000+442.7% Margins · derivedOperating margin-25.4%−17.8 pt vs Q2 2020
Net margin-8.4%−68.1 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 13, 2021 · 44 d after period end